North America Plasma Fractionation Market

North America Plasma Fractionation Market Size (2023 to 2028)

The size of the Plasma Fractionation Market in North America was worth USD 7.00 billion in 2023. This value is forecasted to be growing at a CAGR of 8.3% and value USD 10.42 billion by 2028. Increasing the use of immunoglobulins in several therapeutic areas, increasing the aged population, and the rise in prevalence of rare diseases are primarily driving the growth of the North American plasma fractionation market. 

The growing utilization of immunoglobulins in various therapeutic areas is one of the major factors propelling the plasma fractionation market in North America. Plasma fractionation is a crucial process performed subsequent to plasma collection from donors that involve the division of plasma into distinct fractions or proteins. Plasma is a rich source of essential nutrients, hormones and proteins and finds diverse applications in treating severe health conditions. Through plasma fractionation techniques, components such as antibiotics, clotting factors and fibrinogen are extracted and utilized as therapeutic interventions for individuals experiencing trauma, shock, burns and immune deficiency disorders. This process plays a vital role in addressing critical medical needs and contributes to the advancement of healthcare in the region.

The growing prevalence of infections, driven by factors such as lifestyle changes, heightened exposure to environmental pollutants, genetic predispositions, alterations in blood parameters and occupational exposure to unhygienic conditions drive the growth of the North American plasma fractionation market. Plasma, being abundant in antibodies, plays a vital role in facilitating the rapid recovery of individuals grappling with infections or injuries. Following purification, donor plasma is transfused to individuals afflicted by the same virus, enabling effective treatment. Moreover, chronic infections caused by hepatitis viruses and the Human Immunodeficiency Virus are also addressed through plasma therapy. This therapeutic approach harnesses the power of plasma to combat infectious diseases and enhance patient outcomes.

The continuous advancements in the development of plasma fractionation techniques drive the growth of the North American plasma fractionation market. Researchers are dedicated to expanding the applications of plasma fractionation products across various treatment areas, with the aim of improving patient outcomes and quality of life. Concurrently, manufacturers within the region prioritize the development of cutting-edge devices essential for the fractionation process. The substantial investments in research and development, strong government support and a surge in approvals for novel products further propel the regional market growth.

The high cost associated with certain plasma therapies, shortage of skilled professionals, inadequate infrastructure facilities, stringent regulations governing plasma therapy, the complexity of purification technologies and lengthy approval processes for novel drugs impede the plasma fractionation market growth in the North American region. The side effects associated with plasma-related products and therapies such as weakness, muscle spasms and numbness around the mouth hinder the regional market growth.

This research report on North America Plasma Fractionation Market has been segmented and sub-segmented into the following categories:

By Product: 

• Albumin
• Immunoglobulin
• Factor VIII
• Protease Inhibitors

By Application: 

• Neurology
• Hematology
• Rheumatology
• Pulmonology
• Immunology

By End User: 

• Hospitals
• Clinical Laboratories

By Country: 

• The United States
• Canada
• Rest of North America

The North American region had the largest share of the global market in 2022 and the lead of the North American region is estimated to continue throughout the forecast period owing to factors such as increasing awareness about the benefits of plasma therapies and rapid adoption of advanced treatment procedures for infectious diseases.

The U.S. accounted for the most significant share of the North American market in 2022 and the domination of the U.S. in the North American market is expected to continue throughout the forecast period. Plasma, essential for the fractionation process, serves as a vital raw material to produce lifesaving products. The United States boasts a substantial supply of plasma for fractionation, facilitated by a network of paid frequent donors. This contributes to the country's position as one of the largest suppliers of plasma fractionation worldwide.

Canada is predicted to hold a substantial share of the global market during the forecast period owing to factors such as the increasing number of laboratories equipped for the fractionation process, the presence of clinical trial centers, the availability of donation centers and the growing presence of key industry players.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the North American plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).